GILEAD SCIENCES SL
- Country
- ๐ช๐ธSpain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
- First Posted Date
- 2004-12-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6560
- Registration Number
- NCT00099788
- Locations
- ๐บ๐ธ
The TIMI Study Group, Boston, Massachusetts, United States
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 173
- Registration Number
- NCT00095121
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 372
- Registration Number
- NCT00091598
- Locations
- ๐บ๐ธ
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธBrentwood Biomedical Research Institute, Los Angeles, California, United States
๐บ๐ธMedical College of Georgia, Augusta, Georgia, United States
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
- Conditions
- First Posted Date
- 2004-09-10
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT00091429
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00003338
- Locations
- ๐บ๐ธ
Nuclear Physicians Ltd., Cuyahoga Falls, Ohio, United States
๐ฆ๐นInnsbruck Universitaetsklinik, Innsbruck, Austria
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT00003337
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธMarlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
๐บ๐ธUniversity of Texas- Houston Medical School, Houston, Texas, United States
Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 175
- Registration Number
- NCT00077948
- Locations
- ๐บ๐ธ
University of Utah, Salt Lake City, Utah, United States
๐บ๐ธUniversity of Colorado, Denver, Colorado, United States
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B
- Conditions
- First Posted Date
- 2003-10-17
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT00071201
- Locations
- ๐บ๐ธ
Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, California, United States
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
- Conditions
- First Posted Date
- 2003-05-28
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00061425
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT00054834
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States